1/Bt/ 1c,R. 1 vv11ti. An intcd-discpilinai-n rcti(id oit Ciassitiving and mointiioring incdicatlliii crriirs l/j flisp Plharm19 t9 ;,42.: 1 24-2.
14 Hiatt HH1. Barnc I am in reflective mood as I lie here in the sunshine at the end of mx life. Breast cancer has caught up with me, after eight good y'ears. It seems a common disease in Britain, and the evidence is strong that it is on the increase. Snmall wonder that people working with the discase desperately want to do something. Currently the main effort is in breast screening, with millions of pounds being put into a national programme, as recommcnded by the working group chaired by Professor Sir Patrick Forrest.
What's the use of breast screening?
I want to pLut the question, Are we going the right waI to provide the best possible benefit?
First of all, screening is always a second best, an admission of failure of prevention or treatment. As we are unlikelyN to be able to prevent the disease what is required is successful treatment-and I don't mean even more aggressive adjuvant chemotherapy: I mean a treatment which works, which offers some kind of normal life. I don't want half promises of several years or a 50%S, chance of cure after surgery-it simply isn't good enough for women with the disease. As an example, Lippman believes that breast cancer could be the next human cancer capable of treatment and is working on innovative measures based on growth factors.' Others are using genetic approaches.
The next point to consider is, What can screening actually achieve? Two randomised trials, the Health Insurance Plan and the Swedish two county trial, showed a reduction in mortalitv of 30(% in women offered screening. Other trials, such as the Malm6,4 United Kingdom,' and Edinburgh (unpublished) trials, found a non-significant reduction in mortality.
W'e cannot ignore them, and it is not enough to say that our techniques weren't good enough a few years ago but are adequate now. Wre all know that mammography is an unsuitable screening test: it is technologically difficult to perform, the pictures are difficult to interpret, it has a high false positive rate, and we don't know how often to carry it out. We can no longer ignore the possibility that screening may not reduce mortality in women of any age, however disappointing this may be. Another problem is that screening is offered to onlIy the small proportion of women aged 50-64, there being no evidence that it is of bcnefit to other women. When we calculate the number of women likely to benefit each vear we find that it is a surprisingly small BAIJ VOLUME 299percentage of those who develop breast cancer. For example, of 2400 new patients with the disease seen annually in Scotland, 800 are aged 50-64, 270 will be invited for screening, 180 will attend, and 54 will benefit if there is a 30% improvement in mortality. Of course, it won't be like that because a larger number of cancers will be detected at the first visit and many fewer subsequently. Nevertheless, it is clear that the proportion of women with breast cancer who potentially may benefit is small. Some would prefer to exclude the over 65s from this cost-benefit calculation, but why should we take such an approach to the elderly? We must also note that the benefit is a reduction in mortality. This is not offering any certainty of cure or normal life to the women who attend, merely a prolongation of years for a few. Not only that: we cannot predict who will have these extra years.
It seems now that the Forrest committee was premature in its recommendation. At the time screening certainly seemed more likely to be of benefit than it does now, but I cannot help believing that it was a political decision. The government is prepared to put a large amount of scarce resources into a national breast screening programme, yet is unwilling to take on the tobacco industry at a political level; this despite overwhelming evidence that a truly preventive programme would save thousands of lives each year from lung cancer and other diseases. It was clearly a matter of politics, a decision taken in an election year and now out of perspective. Maureen Roberts tumours found on screening by mastectomy or local excision with conservation of the breast. Policies will vary, but it has already been expressed by many surgeons that "as we should give these women the best possible chance they should have mastectomy." Others will believe in conservation and use it as a bonus point for screening-"you save your breast if the tumour is found when it is small."
As no one knows how to treat non-invasive cancer many surgeons will advocate mastectomy and many women may prefer this. On the other hand, a national trial is being proposed based on conservation and systemic measures. The implication is that treatment will be different in different parts of Britain.
What's to be done?
I've drawn a dismal picture of screening, but it can be improved. I believe that the first thing is to create a nationwide, high quality diagnostic service for breast disease for women of all ages. The new screening clinics could form the basis. They require good clinical staff and surgical back up, cannot be radiological alone (though quality of mammography is of extreme importance), and must offer easy access for women and general practitioners. Clinicians, preferably women, would gain experience of the whole range of breast disease and its management.
The clinics should be run firmly in the context of health care and be sympathetic, open, and truthful, so that women can discuss problems with ease. A programme needs to be set up to encourage women to attend early, to try to reduce the number who currently present with inoperable disease (35%). Women could be made to feel that these clinics (or centres) are their own. As women, especially older women, feel vulnerable to a variety of conditions other services should be offered. The Industrial oxygen might cause harm in two ways. Firstly, in any application, given that the oxygen concentration is 96%, 4% less oxygen will be delivered than shown on the flowmeter. For anaesthetic applications oxygen is invariably used at greater concentrations than is strictly necessary, so that the small fall in concentration would not result in hypoxaemia; 30% oxygen concentration would fall to 28 8%, way above concentrations that might induce hypoxaemia. The most critical application of oxygen treatment is to reduce hypoxaemia in respiratory failure. Here 24% oxygen may be used to increase arterial oxygen saturation while reducing the risk of carbon dioxide retention. A 4% fall in oxygen concentration of the gas driving the venturi mask would have a marginal effect only on the oxygen concentration delivered. Secondly, the source of industrial oxygen might be contaminated with substances that could harm patients. I have indicated that the distillation process removes such contaminants, and my colleague never experienced problems attributable to such contamination. This suggests that the risk is insignificant. Nevertheless, any doctor using industrial oxygen should arrange for analysis of a sample, and if contaminants other than nitrogen and the inert gases were present in concentrations of more than a few parts per million another source of oxygen should be sought. In particular, oxygen concentrators are proving to be efficient and economical in developing countries.
Though availability and cost have undoubtedly led to the use of industrial oxygen one other benefit related to its use is that the 4% of nitrogen and inert gases present may help to prevent the closure of alveoli associated with the use of gases that can be totally absorbed-namely, 100% oxygen and nitrous oxide.-J M CUNDY, consultant anaesthetist, London
